Description

ABT-510 is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD)[1][2].—COVID-19-immunoregulation–C46H83N13O11—-[1]Isenberg JS, et.al. Differential effects of ABT-510 and a CD36-binding peptide derived from the type 1 repeats of thrombospondin-1 on fatty acid uptake, nitric oxide signaling, and caspase activation in vascular cells. Biochem Pharmacol. 2008 Feb 15;75(4):875-82. |[2]Greenaway J, et al. ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer. Mol Cancer Ther. 2009 Jan;8(1):64-74.|[3]Punekar S, et al. Thrombospondin 1 and its mimetic peptide ABT-510 decrease angiogenesis and inflammation in a murine model of inflammatory bowel disease. Pathobiology. 2008;75(1):9-21. –251579-55-2–994.23—-CC(N(C)CC(NCC(N[C@@H](C(C)C)C(N[C@H]([C@@H](C)CC)C(N[C@@H]([C@H](O)C)C(N[C@@H](CCC)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CCCNC(N)=N)C(N1[C@@H](CCC1)C(NCC)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O–Cancer; Inflammation/Immunology–10 mM in DMSO–Apoptosis—-Apoptosis–Peptides